Physician profile
Sammy D Pishanidar
NPI 1366783532
$13,564.88
in general payments reported to CMS, 2019-2025
52 companies · $2,420 in 2025
The $2,420 reported for 2025 was more than what 81% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $466 · 2021: $2,323 · 2022: $1,958 · 2023: $3,044 · 2024: $2,916 · 2025: $2,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,380.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,070.37 | 2021-2025 | |
| Sk Life Science, INC. | $1,221.49 | 2020-2025 | |
| Medtronic, INC. | $937.13 | 2023-2025 | Linq II, Micra |
| Takeda Pharmaceuticals U.S.A., INC. | $630.69 | 2021-2025 | Hyqvia, Gammagard Liquid |
| Amgen INC. | $466.14 | 2020-2025 | Uplizna |
| Allergan, INC. | $462.91 | 2020-2022 | |
| Grifols USA, LLC | $458.03 | 2022-2025 | Gamunex-C |
| Eisai INC. | $454.30 | 2023-2025 | |
| Pfizer INC. | $453.19 | 2023-2025 | |
| Lundbeck LLC | $420.66 | 2020-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $384.28 | 2022-2025 | Vyvgart |
| Janssen Pharmaceuticals, INC | $354.42 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $334.35 | 2020-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $248.86 | 2020-2024 | Ultomiris |
| Ucb, INC. | $224.07 | 2021-2024 | Briviact |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sammy Pishanidar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.